AAD data show how weight-loss drugs are reshaping demand and why faster, lower-commitment injectables may be arriving at the right moment.
There is an irony at the center of the GLP-1 boom. Drugs designed to help people lose weight and improve metabolic health are being hailed as some of the most important medical advances of the decade. But as more patients slim down, a different kind of concern is showing up in doctors’ offices: what happens when feeling healthier also changes the face you see in the mirror?
At the 2026 American Academy of Dermatology Meeting (AAD), Allergan Aesthetics, an AbbVie company, leaned directly into that question. Through four poster presentations, the company highlighted both an investigational fast-acting wrinkle treatment and new survey data suggesting that patients on GLP-1 agonists for weight loss are becoming a fast-growing force in aesthetic medicine [1].
That combination is not accidental. The lines between longevity, metabolic health and aesthetics are blurring and companies that understand that overlap early may be the ones best positioned to grow.
“At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio,” said Dr John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics. “Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients’ aesthetic concerns.”
The GLP-1 patient is becoming an aesthetics patient
The most revealing data Allergan presented may not have come from a drug trial at all, but from a survey.
In an electronic survey of US healthcare professionals who treat aesthetic concerns in patients using GLP-1 agonists for weight loss, Allergan found that 52% of GLP-1-treated patients express concern about their facial appearance as they move through treatment.
That number matters because it captures something clinicians have been noticing in real time: as patients lose weight, they may also lose facial volume. The result can be a more hollow, drawn or older-looking appearance – a phenomenon that has become familiar enough in popular culture to spark endless commentary, but is now clearly becoming a commercial category.
Even more telling, clinicians reported that 32% of GLP-1-treated patients seeking aesthetic care are new to their practice. In other words, this is not just existing aesthetics consumers buying a bit more. It is a new funnel.
That should get investors’ attention. If a third of these patients are first-timers, GLP-1s are not simply shifting demand within the aesthetics market; they may be enlarging it. But patients are not asking for “more.”
The survey data also reveal something more nuanced than a simple growth story. The top barrier keeping these patients from moving forward with aesthetic treatment was cost, cited by 82% of healthcare professionals. The second was fear of unnatural results, cited by 58%.
The second point may be the more important one. People using GLP-1s are often already navigating a deeply personal transformation. They are changing how they eat, how they look, how their clothes fit and often how other people react to them. Many do not want to emerge from that process looking “worked on.” They want to look like themselves, just less tired, less gaunt, less abruptly changed.
That is where the aesthetics industry may need to mature. The old sales logic of “more product, more correction” does not map neatly onto this new patient. What seems to be emerging instead is a demand for lower-friction, lower-commitment, more natural-looking interventions. The winning products may be the ones that feel less like a makeover and more like a tune-up.
Why TrenibotE fits the moment
Allergan also used AAD to spotlight new Phase 3 data on trenibotulinumtoxinE, or TrenibotE. The product is still investigational, but its pitch is that it works fast and does not last as long.
Unlike traditional wrinkle-relaxing neurotoxins, which can take a few days to show visible results and often stick around for months, TrenibotE is characterized by rapid results – as early as eight hours after administration, according to the company’s earliest assessment time – and a shorter duration of effect of around two to three weeks.
For patients nervous about injectables, that could be a meaningful psychological unlock. A fast-on, fast-off product gives people a way to “test drive” treatment without feeling locked into a face they may not recognize for the next quarter.
Allergan’s 18-week, open-label Phase 3 study looked at repeat use of TrenibotE for glabellar lines, the vertical frown lines between the eyebrows. Across up to three open-label treatments, the company said the treatment was well-tolerated, with a consistent safety profile, no new safety concerns and no development of neutralizing antibodies. It also rapidly reduced glabellar line severity, with consistent efficacy across repeat treatments, as assessed by both investigators and participants. If approved, TrenibotE would be the first botulinum toxin type E available to patients.
It would be easy to dismiss all this as opportunism by the cosmetics industry. And yes, there is always a risk of over-medicalizing appearance, but that is not the whole story.
Longevity has never been just about adding years. It is about how people inhabit those years. Physically, socially and psychologically. As GLP-1s move from blockbuster drugs to long-term lifestyle therapies, the downstream effects are becoming more visible. People may be metabolically healthier and medically better off, but still unsettled by how rapid weight loss changes their appearance.
Allergan’s AAD data suggest the company clearly sees that. The opportunity is not simply to sell more injectables. It is to serve a new kind of patient: one arriving through metabolic medicine, cautious about looking unnatural and increasingly willing to pay for treatments that feel reversible, subtle and aligned with a broader sense of well-being.
